Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an upgrade yesterday by Piper Jaffray and analysts at Janney Capital beginning coverage of the stock with a Buy rating and a $3 price target. CORT climbed just over 10% on Thursday to close at $1.63 a share, its best finish since early November.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs